Home About ATSDR Press Room A-Z Index Glossary Employment Training Contact Us CDC  
ATSDR/DHHS Agency for Toxic Substances and Disease Registry Agency for Toxic Substances and Disease Registry Department of Health and Human Services ATSDR en Español

Search:

Section Contents
 
Learning Objectives
Introduction
Respiratory Support
Key Points
Progress Check
 
Case Contents
 
Table of Contents
Cover Page
How to Use the Course
Initial Check
Mass Casualty Events
Cholinesterase Inhibitors
Pathological Conditions
Cholinergic Toxidrome
Nicotinic Receptors
Muscarinic Receptors
Nicotinic/Muscarinic Mixture
Signs and Symptoms
Laboratory Tests
Differential Diagnosis
Pediatric Cases
Exposure History
RBC & Serum Tests
Inhibitors & Byproducts
Management Strategies
Secondary Exposure
First-Line Medications
Medications: Atropine
Medications: Pralidoxime
Medications: Diazepam
Antidote Stocking
Deprecated Treatments
Medico-Legal Issues
Intermediate Syndrome
Delayed Neuropathy
Chronic Neurotoxicity
Other Issues
Posttest
Literature Cited
 
Related Documents
 
MMG: Nerve Agents
ToxFAQs™: Nerve Agents
 
Case Studies (CSEM)
 
CSEM Home
Continuing Education
Online Registration
 
ATSDR Resources
 
Case Studies (CSEM)
Exposure Pathways
GATHER (GIS)
Health Assessments
Health Statements
Interaction Profiles
Interactive Learning
Managing Incidents
Medical Guidelines
Minimal Risk Levels
Priority List
ToxFAQs™
ToxFAQs™ CABS
Toxicological Profiles
Toxicology Curriculum
 
External Resources
 
CDC
eLCOSH
EPA
Healthfinder®
Medline Plus
NCEH
NIEHS
NIOSH
OSHA
 

Agency for Toxic Substances and Disease Registry
Case Studies in Environmental Medicine (CSEM) 

Cholinesterase Inhibitors
Including Insecticides and Chemical Warfare Nerve Agents
Part 4: The Cholinergic Toxidrome
Section 11: Management of the Cholinergic Toxidrome
Management Strategy 2: Supportive Care


Learning Objectives

Upon completion of this section, you should be able to

  • Identify the most important organ system requiring supportive care in patients suffering from the cholinergic toxidrome.

Introduction

Monitoring and intensive supportive care are critical components of patient management in severe poisoning cases. Monitoring of exposed patients may need to be prolonged because of the possibility of delayed onset of effects from cholinesterase inhibitors.


Importance of Respiratory Support

Death from cholinesterase inhibitor poisoning is usually due to respiratory failure from a combination of: (Zwiener and Ginsburg 1988; Sofer, Tal et al. 1989; Reigart and Roberts 1999)

  • Bronchoconstriction.
  • Bronchorrhea.
  • Central respiratory depression.
  • Weakness or paralysis of respiratory muscles.

Therefore, early, aggressive respiratory support is a mainstay of treatment, including endotracheal intubation and mechanical ventilation when indicated.


Key Points

  • Supportive care plays a critical role in the medical management of the cholinergic toxidrome.
  • Aggressive respiratory support is particularly important, since respiratory failure is the usual cause of fatality.

Progress Check

33. The most important aspect of supportive care for cholinesterase inhibitor toxicity is aimed at: (Choose the ONE BEST answer)

A. The cardiovascular system.
B. The respiratory system.
C. The liver and kidneys.
D. The digestive tract.
E. None of the above.

Answer:

To review relevant content, see Importance of Respiratory Support in this section.


Previous Section

Next Section

Revised 2007-10-16.